Investors of Humacyte Stock With Financial Losses Encouraged to Contact Kehoe Law Firm, P.C.
Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Humacyte, Inc. (“Humacyte” or the “Company”) (NASDAQ: HUMA).
INVESTORS OF HUMACYTE STOCK WITH FINANCIAL LOSSES CAN CLICK HERE OR EMAIL [email protected] TO CONTACT KEHOE LAW FIRM, P.C. TO DISCUSS THE SECURITIES CLASS ACTION INVESTIGATION AND POTENTIAL LEGAL CLAIMS.
On October 17, 2024, the stock price of Humacyte dropped more than 16%, after the FDA disclosed in a Form 483 multiple violations at the Company’s Durham, North Carolina facility, including but not limited to, inadequate quality oversight and no microbial quality assurance and testing. These violations were found during inspections that took place between April 1 through April 5, 2024.
The findings by the FDA may have run counter to statements made by the Company in May 2024 that the inspections were “very successful” and raises concerns about the Company’s transparency and commitment to regulatory compliance.
HUMACYTE INVESTORS WITH FINANCIAL LOSSES ALSO CAN CONTACT MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected], [email protected], TO LEARN MORE ABOUT THE HUMACYTE SECURITIES CLASS ACTION INVESTIGATION AND POTENTIAL LEGAL CLAIMS.
